DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients

Information source: Sanquin
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypogammaglobulinemia

Intervention: IVIG-L (Drug)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: Sanquin

Official(s) and/or principal investigator(s):
J WM van der Meer, MD, PhD, Principal Investigator, Affiliation: UMC St Radboud Nijmegen


The kinetics, efficacy and safety of a liquid intravenous immunoglobulin product, IVIG-L, were studied in patients with hypogammaglobulinemia, who are regularly treated with intravenous immunoglobulin substitution therapy.

Clinical Details

Official title: Kinetics, Efficacy and Safety of IVIG-L (Human Normal Intravenous Immunoglobulin for Intravenous Use) in Hypogammaglobulinemia Patients

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Kinetics of IVIG-L in patients with hypogammaglobulinemia

Efficacy of IVIG-L in patients with hypogammaglobulinemia

Safety of IVIG-L in patients with hypogammaglobulinemia

Secondary outcome:

To compare the IgG trough level

To compare dosage and treatment intervals

Detailed description: Sanquin has developed, in cooperation with the Finnish Red Cross Blood Transfusion Service (FRCBTS), a liquid intravenous immunoglobulin product, IVIG-L. The liquid formulation of intravenous immunoglobulin simplifies the infusion, eliminates possible mistakes in the reconstitution with water for injections and reduces the space requirements in storage. In addition to the donor selection and donor screening, several viral safety steps have been included into the production process. In this clinical trial, the efficacy and safety of IVIG-L in patients with hypogammaglobulinemia, who are regularly treated with intravenous immunoglobulin substitution therapy, will be studied. IVIG-L will also be studied in patients with chronic ITP (KB98001). Data from both studies will be used for an application for marketing authorisation in Finland and the Netherlands.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Primary a- or hypogammaglobulinemia, particularly patients with X-linked

agammaglobulinemia (XLA) or Common Variable Immunodeficiency (CVID)

- Used to replacement treatment with intravenous immunoglobulin with 2-4 week intervals

- A stable clinical situation (no activity of any other disease; a stable

immunoglobulin dose)

- Age > 18 years

- The patient/legally acceptable representative has signed the consent form

Exclusion Criteria:

- Treatment with any other investigational drug within 7 days before study entry or

previous enrolment in this study

- Known allergic reactions to human plasma or plasma products

- Have an ongoing progressive terminal disease, including HIV infection

- Pregnancy or lactation

- Known insufficiency of coronary or cerebral circulation

- Have renal insufficiency (plasma creatinine > 115┬Ámol/L)

- Have an ongoing active disease causing general symptoms, e. g. chronic active

hepatitis, persistent enterovirus infection.

- Have IgA deficiency, and anti-IgA antibodies have been detected

- Active systemic lupus erythematosus (SLE)

Locations and Contacts

Medical Centre Alkmaar, Alkmaar 1815 JD, Netherlands

Academic Medical Centre, Amsterdam 1100 DD, Netherlands

Academic Hospital Groningen, Groningen 9700 RB, Netherlands

LUMC, Leiden 2333 ZA, Netherlands

UMC St. Radboud, Nijmegen 6525 GA, Netherlands

Leyenburg Hospital, The Hague 2545 CH, Netherlands

Additional Information

Starting date: May 2001
Last updated: April 18, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017